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A B S T R A C T
Over 4.5 billion people are at risk of infection with soil transmitted helminths and there are concerns about the
development of resistance to the handful of frontline nematocides in endemic populations. We investigated the
anti-nematode efficacy of a series of polypyridylruthenium(II) complexes and showed they were active against
L3 and adult stages of Trichuris muris, the rodent homologue of the causative agent of human trichuriasis, T.
trichiura. One of the compounds, Rubb12-mono, which was among the most potent in its ability to kill L3
(IC50 = 3.1 ± 0.4 μM) and adult (IC50 = 5.2 ± 0.3 μM) stage worms was assessed for efficacy in a mouse
model of trichuriasis by administering 3 consecutive daily oral doses of the drug 3 weeks post infection with the
murine whipworm Trichuris muris. Mice treated with Rubb12-mono showed an average 66% reduction
(P = 0.015) in faecal egg count over two independent trials. The drugs partially exerted their activity through
inhibition of acetylcholinesterases, as worms treated in vitro and in vivo showed significant decreases in the
activity of this class of enzymes. Our data show that ruthenium complexes are effective against T. muris, a model
gastro-intestinal nematode and soil-transmitted helminth. Further, knowledge of the target of ruthenium drugs
can facilitate modification of current compounds to identify analogues which are even more effective and se-
lective against Trichuris and other helminths of human and veterinary importance.
1. Introduction
More than 4.5 billion people worldwide are at risk of infection by
soil-transmitted helminths (STHs) and over one-third of this number are
infected with these parasites (Ascaris lumbricoides – 0.8 billion infec-
tions), whipworm (Trichuris trichiura - 0.46 billion) and hookworms
(Necator americanus and Ancylostoma duodenale - 0.44 billion) (Pullan
et al., 2014). STHs are prevalent in more than 100 countries (Gan et al.,
2009), particularly in developing tropical and subtropical regions (Sub-
Saharan Africa, East Asia and South America) where the hygiene con-
ditions and sanitation practises are poor.
STH infections rarely cause death; rather, they cause chronic and
insidious effects on the host's health with clinical manifestations cor-
relating with infection intensity. Heavy infection causes extensive
morbidities such as intestinal disturbances, nutrition loss, physical and
intellectual growth retardation and severe anaemia, particularly in pre-
and school-aged children (Brooker et al., 1999; Stoltzfus et al., 2000).
STH remains a serious problem in public health with a global burden of
4.98 million years lost to disability (YLDs) (Pullan et al., 2014), which
approaches that caused by malaria.
Despite the public-health importance of these infections, these dis-
eases have been neglected by the medical and international commu-
nities, predominantly because they are concentrated in very poor
communities and the diseases can often be overshadowed by other
public health or social issues. But, in recent years, the control of STH
has become more important in public health management, and combat
strategies have been proposed after the World Health Assembly re-
solution in 2001, with the administration of anthelmintics being the
cornerstone of these programmes (Loukas and Bethony, 2008).
Five drugs (albendazole, mebendazole, pyrantel pamoate,
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levamisole, and ivermectin) are currently available for the treatment of
STH, yet control programmes rely heavily on only the two benzimida-
zoles (albendazole and mebendazole) because of economical and op-
erational feasibility (Tritten et al., 2011).
There is no direct evidence for emerging resistance to any of the
current anthelmintics in human helminth populations, however, low
cure rates have been reported for T. trichiura and hookworm infections
(Keiser and Utzinger, 2010). Repeated and prolonged administration of
these anthelmintics, necessitated by sub-optimal drug efficacies, in-
creases the risk of resistance developing and has already been well
documented among nematodes of veterinary importance, and is in-
creasing in frequency as a consequence of extensive use of benzimida-
zoles over extended periods of time (Kaplan, 2004).
Among potential targets for nematode chemotherapy are acet-
ylcholinesterases (AChEs). These enzymes catalyse the rapid break-
down of the neurotransmitter acetylcholine (ACh) in both central and
peripheral nervous systems of eukaryotic organisms, and so control
neuronal function (Massoulie et al., 1993). In addition to controlling
cholinergic synapses, multiple isoforms of the enzyme are secreted from
many nematodes in large amounts and have been implicated in med-
iating pathogenesis of nematode infection by modulating the host im-
mune system through the disruption of host cholinergic signalling
(Selkirk et al., 2005; Vaux et al., 2016) and providing acetate and
choline precursors for helminth metabolism (Lee, 1996).
With respect to its termination of synaptic transmission, inhibition
of AChE produces an excess accumulation of ACh and overstimulation
of its receptors, causing uncoordinated neuromuscular function that
often results in death due to respiratory paralysis (Thapa et al., 2017).
As such, AChE inhibitors are widely used as pesticides (Kwong, 2002)
and anthelmintics (Orhan, 2013). Indeed, metrifonate, an organopho-
sphorus AChE inhibitor originally used as an insecticide, has also been
used for the treatment of human and veterinary nematode infections
(Thompson et al., 1996) but now has limited use as a therapeutic be-
cause of off-target toxicity (Kramer et al., 2014). Moreover, the front-
line nematocides all target the neuromusculature of these parasites
(Thompson et al., 1996) although they are not necessarily inhibitors of
AChE.
In addition to organophosphates, mono-nuclear chemical complexes
of the transition metal ruthenium have been shown to target and inhibit
enzymes such as AChE (Vyas et al., 2014), and there are numerous
recent studies documenting the efficacy of polypyridylruthenium(II)
complexes against a variety of different microbial pathogens (Li et al.,
2011; Pandrala et al., 2013; Gorle et al., 2014). Unlike their organo-
phosphorus counterparts, ruthenium complexes are speculated to exert
their inhibitory effects through a combination of electrostatic and hy-
drophobic interactions at the peripheral anionic (PAS) site of AChE,
which is located at the gate of the enzyme's catalytic gorge (Bourne
et al., 2005), and not through direct interaction with the active site.
Ruthenium complexes are thought to be less toxic to human cells than
small-molecule inhibitors because of this mode of inhibition and also
because the overall neutral charge in the outer membrane leaflet of
eukaryotic cells (Mason et al., 2007) creates a greatly reduced capacity
for electrostatic interaction with the metal compounds (Gorle et al.,
2016).
Herein, we demonstrate the AChE-inhibitory action of two mono-
nuclear and a series of di-, tri- and tetra-nuclear polypyridylruthenium
(II) (ruthenium) complexes linked by the bis[4(4′-methyl-2,2′-bipyr-
idyl)]-1,n-alkane ligand (“bbn”; n = 7, 10, 12 and 16) against extracts
of T. muris and Ancylostoma caninum (helminths used as models of
human trichuriasis and hookworm infection, respectively) and both
adult and L3 stage T. muris parasites in vitro. We also show the in vivo
efficacy of one of these ruthenium complexes (Rubb12-mono) in a
mouse model of trichuriasis, providing evidence that drugs based on
these compounds could be a valuable addition to the chemotherapeutic
arsenal against both human and veterinary nematode infections.
2. Materials and methods
2.1. Nomenclature and preparation of ruthenium complexes
[Ru(phen)2(Me2bpy)]2+ (phen = 1,10-phenanthroline;
Me2bpy = 4,4′-dimethyl-2,2′-bipridine) and the mononuclear (Rubbn-
mono), dinuclear (Rubbn-di), trinuclear (Rubbn-tri), tetranuclear linear
(Rubbn-tl) and tetranuclear non-linear (Rubbn-tnl) poly-
pyridylruthenium(II) complexes (Fig. 1) were synthesised using the
appropriate bis[4′-(4-methyl-2,2′-bipyridyl)]-1,n-alkane ligand (bbn) as
Fig. 1. The inert tri-nuclear (Rubbn-tri), linear tetra-nuclear (Rubbn-tl) and non-linear tetra-nuclear (Rubbntnl) ruthenium complexes.
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previously described (Gorle et al., 2014). All ruthenium complexes
were chloride salts and were dissolved in H2O at stock concentrations of
1 mM.
2.2. Animals and parasites
Six-to eight-week old male B10.BR mice were purchased from the
Animal Resource Centre, Canningvale, Western Australia and allowed
to acclimatise for one week before infection. Mice were orally infected
with 200 μl of PBS containing approximately 200 live embyronated T.
muris eggs. All animals were kept in groups of 5 mice in cages with free
access to water and food and with a 12-h light/dark cycle. Third stage
larvae (L3) and adult worms were harvested from the caecum by sa-
crificing the mice after three weeks and five weeks, respectively. Both
stages were washed with PBS containing 2 × antibiotic/antimycotic
(AA) and used for either extract preparation (adult) or in vitro experi-
ments (adult and L3).
2.3. Parasite extract preparation
Freshly harvested adult T. muris or A. caninum (thawed from -80 °C
stocks) were homogenised (10 parasites/200 μl) in PBS containing 1%
Triton X-100, 40 mM Tris-HCl, pH 7.4, at 4 °C using a TissueLyser II
(Qiagen) and the supernatant collected by centrifugation at 15,000 g for
60 min at 4 °C. Protein concentration was determined using the Pierce
BCA Protein Assay kit (Thermofisher), aliquoted and stored at -80 °C
until use.
2.4. Enzyme activity in parasite extracts and inhibition assays
AChE activity in Triton X-100-soluble adult T. muris and A. caninum
extracts was determined in a Polarstar Omega microplate reader (200 μl
final volume in 96-well plates) using the Ellman method (Ellman et al.,
1961). Extracts were serially diluted (40-10 μg) in AChE assay buffer
(0.1 M sodium phosphate, pH 7.4), 2 mM acetyl-thiocholine (AcSCh)
and 0.5 mM 5,5′-dithio-bis(2-nitrobenzoic acid) (DTNB) were added
and absorbance was measured (405 nm) every 10 min for 5 h at 37 °C.
Specific activity was calculated using the initial velocity of the reaction.
For AChE inhibition assays, extract equal to a specific activity of
0.55 nmol/min/well (T. muris - 30 μg, A. caninum – 20 μg) were diluted
in AChE assay buffer to a final volume of 170 μl and pre-incubated with
ruthenium complexes (10 nM–100 μM) for 20 min at RT. AcSCh and
DTNB were added at 2 mM and 0.5 mM, respectively and absorbance
was measured (405 nm) every 10 min for 5 h at 37 °C. Inhibition for
each sample was calculated relative to the negative control (reactions
without ruthenium complexes) and reactions were performed in du-
plicate.
2.5. In vitro activity of ruthenium complexes against adult and L3 stage T.
muris
Ruthenium complexes were dissolved in sterile PBS for use in the
assay. Adult or L3 stage worms were transferred in groups of 4 into each
well of a 48-well plate containing 0.5 ml pre-warmed RPMI medium
supplemented with 2 × AA and cultured with ruthenium complexes
(50 μM). Control worms were treated with the PBS vehicle. All worms
were incubated at 37 °C and 5% CO2 for 72 h and monitored every 24 h
for motility by microscopic examination (20 × ). The viability of the
worms was evaluated according to previously reported protocols
(Tritten et al., 2012; Keiser et al., 2013) using a motility scale from 0 to
3 (0 = dead, 1 = very low motility, 2 = low motility, 3 = normal
motility). IC50 values of the two most effective ruthenium complexes
were then similarly tested at different concentrations ranging from
3.125 to 50 μM. Assays were conducted in duplicate and data is re-
presented as the average of these two experiments ± SE. Albendazole
was used at 200 μg/ml - the IC50 previously determined against adult
and L3 stage T. muris (Tritten et al., 2011) - as a positive control in all
experiments.
2.6. Enzyme inhibition studies on ruthenium complex-treated adult T. muris
Groups of five, freshly isolated adult T. muris were cultured in the
presence of sub-lethal concentrations of either Rubb12-mono and
Rubb12-tri (6.25 μM in PBS) or PBS alone in RPMI medium supple-
mented with 2 × AA. Three sets of five worms were used for each drug
tested. Worms were collected after 24 h when they were still motile.
Triton X-100-soluble extracts were made from each set of five worms
(so, three extracts for each drug tested), quantified using the Pierce BCA
Protein Assay kit (Thermofisher) and immediately assayed for AChE
activity. Each assay was technically replicated three times. For each
enzyme assay, activities of drug-treated parasites were expressed re-
lative to worms cultured without ruthenium complexes (negative con-
trols). Data is the average of assays run on triplicate extracts and three
technical replicates of each assay ± SE.
2.7. Tolerability study
In order to determine the appropriate dose of Rubb12-mono to be
used in the in vivo study, the maximum tolerated dose was determined
for the B10.BR mouse strain. Rubb12-mono was administered to groups
of three male mice for three consecutive days. The doses ranged from 5
to 20 mg/kg. Animals were closely monitored for adverse clinical signs
throughout the study and mice showing adverse effects were euthanised
using CO2 asphyxiation. The highest dose that did not cause any ad-
verse clinical signs for three consecutive daily doses was considered to
be the maximum tolerated dose (MTD).
2.8. In vivo efficacy of Rubb12-mono
The in vivo efficacy of Rubb12-mono was tested in two independent
trials. For each trial, groups of nine male B10.BR mice (6-8 weeks old)
were each orally infected with 200 μL of PBS containing approximately
200 live embryonated T. muris eggs. At 28 days p.i., one group was
given three consecutive daily oral doses (200 μl) of Rubb12-mono
(2 × 10 mg/kg in PBS and 1 × 5 mg/kg in PBS) and the other (negative
control group) was given three consecutive daily oral doses (200 μl) of
PBS. Mice were sacrificed at 35 days p.i. and worms were harvested
from the caecum and counted manually using light microscopy
(20 × magnification). The worm burden reduction (WBR) was calcu-
lated as: [[(a − b)/a] × 100], where a = average worm count in the
negative control group and b= average worm count in a treated group.
Faecal samples (approximately 0.1 g) from each individual mouse were
collected 24 h before necropsy, homogenised in 2 ml of saturated NaCl
overnight at 4 °C and the number of eggs counted in triplicate using a
Whitlock McMaster counting chamber. This number was used to de-
termine the number of eggs per gram (EPG) of faeces and reduction
calculated as for WBR. Extracts were prepared from equal numbers of
worms harvested from each individual mouse of each group (trial 1
control – n = 9 mice, trial 1 treatment – n = 6 mice, trial 2 control –
n = 9 mice, trial 2 treatment – n = 7 mice) and assayed in triplicate for
AChE activity. For each trial, differences in AChE activity was calcu-
lated by comparing the average of all extracts from the treatment group
with the average (± SE) of all extracts from the control group.
2.9. Statistical analyses
Statistical analyses were performed using Graphpad Prism 7.
Inhibition curves and IC50 values were generated using sigmoidal dose-
response (variable slope) with a non-linear fit model. One-way ANOVA
with Dunn's multiple comparison was used to determine significance
(p), which was set at 0.05. In the case where only two groups were
compared (in vivo studies), student's t-test with Welch's correction was
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used.
2.10. Animal ethics approval
The James Cook University (JCU) animal ethics committee ap-
proved all experimental work involving animals (ethics approval
number A2271). Mice were raised in cages in the JCU quarantine fa-
cility for the duration of the experiments in compliance with the 2007
Australian Code of Practice for the Care and use of Animals for
Scientific Purposes and the 2001 Queensland Animal Care and
Protection Act. All reasonable efforts were made to minimise animal
suffering.
3. Results
3.1. Inhibition of AChE activity in adult T. muris extracts
A series of ruthenium complexes were screened at 1 μM for AChE
inhibitory activity in T. muris adult parasite extract. Except for [Ru
(phen)2(Me2bpy)]2+ and Rubb12-mono, all complexes inhibited 65-
93% AChE activity (Table 1). The IC50 for each ruthenium complex
against AChE activity was also determined. Except for [Ru
(phen)2(Me2bpy)]2+, all complexes exhibited IC50 values between sub-
to low-micromolar concentrations with Rubb10-tri and Rubb7-tnl being
the most potent, having IC50 values of 61 and 120 nM, respectively
(Table 1).
3.2. Inhibition of AChE activity in adult A. caninum extracts
Since the ruthenium complexes inhibited AChE activity in T. muris
extract, we explored the inhibitory activities of the compounds in ex-
tracts of A. caninum (Table 2). The series displayed a more varied range
of activity than was seen for T. muris, with AChE inhibition ranging
from 18 to 76%. Rubb7-tl and Rubb12-tl showed the greatest inhibitory
activity against A. caninum extracts, with IC50 values of 0.2 ± 0.01 μM
and 0.6 ± 0.03 μM, respectively. AChE inhibition increased with in-
creasing nuclearity of the ruthenium centres only to the level of the
dinuclear complex, with the inhibition by Rubb12-mono < Rubb12-
di ≈ Rubb12-tri ≈ Rubb12-tl. The tetra-linear complexes showed
greater activity compared to their non-linear counterparts and the in-
hibitory activity of the tri-nuclear complexes decreased with increasing
chain length of the linking ligand (bbn) (Table 2) (Fig. 2).
3.3. In vitro effect of ruthenium complexes against L3 and adult T. muris
Four L3 T. muris larvae were cultured in the presence of each ru-
thenium complex (50 μM) and the parasite motility was monitored at
24 and 48 h (Fig. 3). Treatment with Rubb12-mono and Rubb12-tri
complexes resulted in 100% worm death in 24 h, whereas most of the
Table 1
Inhibition and the potency (IC50) of the series of ruthenium complexes against AChE
activity in adult T. muris extracts. Ruthenium complexes that showed the highest potency
are highlighted (bold).
Compound AChE inhibition (%)a, b IC50 (μM)b
[Ru(phen)2(Me2bpy)]2+ 0.7 ± 0.6 31.26 ± 1.17
Rubb7-tri 81.6 ± 0.3 0.29 ± 0.00
Rubb7-tl 76.9 ± 0.5 0.32 ± 0.02
Rubb7-tnl 93.2 ± 0.5 0.12 ± 0.02
Rubb10-tri 86.8 ± 0.7 0.06 ± 0.00
Rubb12-mono 5.0 ± 0.3 2.30 ± 0.25
Rubb12-di 68.7 ± 0.9 0.35 ± 0.08
Rubb12-tri 65.4 ± 0.2 1.00 ± 0.05
Rubb12-tl 81.2 ± 0.1 0.83 ± 0.06
Rubb12-tnl 90.7 ± 0.8 0.24 ± 0.01
Rubb16-tri 76.4 ± 0.7 0.47 ± 0.04
Rubb16-tl 69.5 ± 0.7 0.47 ± 0.04
Rubb16-tnl 91.9 ± 0.0 0.25 ± 0.00
a Inhibition of AChE activity assessed at 1 μM.
b Data represent the mean of duplicate experiments ± SE.
Table 2
Inhibition and the potency (IC50) of the series of ruthenium complexes against AChE
activity in adult A. caninum extracts. Ruthenium complexes that showed the highest
potency are highlighted (bold).
Compound AChE inhibition (%)a, b IC50 (μM)b
[Ru(phen)2(Me2bpy)]2+ 56.8 ± 0.0 0.6 ± 0.0
Rubb7-tri 71.4 ± 1.0 ND
Rubb7-tl 76.6 ± 0.1 0.2 ± 0.0
Rubb7-tnl 47.1 ± 0.5 0.8 ± 0.0
Rubb10-tri 58.5 ± 0.1 1.0 ± 0.0
Rubb12-mono 18.4 ± 3.4 18.1 ± 0.2
Rubb12-di 57.1 ± 1.0 0.8 ± 0.0
Rubb12-tri 55.4 ± 0.4 0.9 ± 0.0
Rubb12-tl 59.7 ± 0.2 0.6 ± 0.0
Rubb12-tnl 39.4 ± 0.7 1.4 ± 0.1
Rubb16-tri 43.6 ± 0.2 ND
Rubb16-tl 37.0 ± 1.0 1.0 ± 0.1
Rubb16-tnl 27.6 ± 2.1 3.5 ± 0.3
a Inhibition of AChE activity assessed at 1 μM.
b Data represent the mean of duplicate experiments ± SE.
Fig. 2. Activity of tetra-nuclear (linear - TL and non-linear - TNL) ruthenium com-
plexes against AChE in A. caninum extracts. IC50 values are the mean of duplicate
experiments± SE. Significance determined by student's t-test. *P≤ 0.05, ***P≤ 0.001.
Fig. 3. Activity of ruthenium complexes against T. muris third stage larvae (L3).
Survival of cultured parasites in RPMI medium after treatment with Ru complexes
(50 μM) for 24 h. Albendazole was used at 200 μg/ml. Experiments were performed in
duplicate and data represents the average of these two experiments ± SE.
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other complexes killed 100% of the worms after 48 h (data not shown).
Subsequently, the most active complexes, Rubb12-mono and Rubb12-tri,
were tested at different concentrations against L3 stage worms and
displayed IC50 values of 3.1 ± 0.4 and 2.3 ± 0.3 μM, respectively
(Table 3). In identical experiments with adult parasites, Rubb12-mono
and Rubb12-tri were the most effective, killing 100% of adult worms in
24 h (Fig. 4). IC50 values were subsequently determined as 3.1 ± 0.4
and 2.3 ± 0.3 μM, respectively (Table 3).
3.4. Mechanism of action of ruthenium complexes against T. muris
Given the AChE inhibitory effect exhibited by ruthenium complexes
against adult parasite extracts and their efficacy in anti-Trichuris assays
in vitro, their mechanism of action was analysed in live adult worms.
Extracts made from parasites cultured for 24 h in the presence of sub-
lethal concentrations of Rubb12-mono and Rubb12 –tri (the two most
effective compounds against both L3 and adult T. muris) were assayed
for AChE activity, and significant reductions were seen in the treated
worms (Rubb12-mono - 42%, P < 0.0001; Rubb12-tri - 44%,
P < 0.0001) compared to controls (Fig. 5).
3.5. Tolerability of Rubb12-mono
The tolerability of Rubb12-mono in mice was evaluated using con-
secutive daily oral doses of 5, 10 and 20 mg/kg. According to standard
practice, the MTD was considered to be the highest dose where no signs
of physical stress were observed. Rubb12-mono was not tolerated at
20 mg/kg (1 out of 3 mice died within 15 min) but did not show any
toxicity at 10 mg/kg, even after three consecutive oral doses. The MTD
of Rubb12-mono was considered to be 10 mg/kg and was used as the
dose in the in vivo efficacy study.
3.6. In vivo efficacy of Rubb12-mono against T. muris
Based on the significant in vitro activity against T. muris adults and
L3 stage worms, Rubb12-mono was further assessed for its in vivo effi-
cacy using a mouse model of T. muris infection. Three weeks after in-
fection, Rubb12-mono was orally administrated once daily for 2 day at
10 mg/kg with a 5 mg/kg dose administered on the third day. Worm
and faecal egg counts were assessed at 5 weeks p.i. (Fig. 6). For trial 1,
Rubb12-mono-treated mice achieved significant reductions in worm
(35%, P = 0.0396) and egg (82%, P = 0.0034) counts, compared to
PBS treated controls. Further, extracts made from worms recovered
from treated mice showed significantly less AChE activity (P= 0.0044)
than extracts from worms recovered from control animals. There was a
non-significant decrease (11%, P = 0.279) in the worm burden of
Rubb12-mono-treated mice in trial 2 compared to controls and no dif-
ference in the AChE activity of extracts made from worms recovered
from treated and control mice. However, the faecal egg count seen in
treated mice was significantly lower (50%, P = 0.0155) than control
animals from this trial. Over the two independent trials, the average
reduction in faecal egg count was 66% (P = 0.015), compared to
controls.
4. Discussion
Over 1.5 billion people are infected with soil-transmitted helminths
(STHs), no anti-STH vaccines are available and there is evidence that
resistance to the handful of drugs used to control this scourge is de-
veloping. In this study, we have investigated the activity of a series of
ruthenium complexes against two model species of STHs - T. muris and
A. caninum - have shown that these compounds are capable of inhibiting
AChE activity in extracts made from the parasites and, at least for T.
muris, the nematocidal action of ruthenium complexes could be par-
tially due to AChE inhibition, an enzyme vital to the neuromuscular
function of these helminths.
With regard to the AChE-inhibitory properties of ruthenium com-
plexes against parasite extracts, no specific relationship between com-
pound structure and activity was observed with T. muris extracts, al-
though all the ruthenium complexes inhibited AChE activity at sub-
micromolar to micromolar concentrations with specific tri- and tetra-
nuclear complexes displaying the most potent activity. Conversely, a
structure/activity relationship was observed for tetra-nuclear ruthe-
nium complex inhibition of A. caninum extracts, with potency in-
creasing with decreasing chain length between the ruthenium centres.
The mononuclear ruthenium complexes are thought to interact with the
Table 3
Potency of Rubb12-mono and Rubb12-tri against L3 and adult stages of T. muris.
Compound IC50 (μM)a,b
L3 adult
Rubb12-mono 3.1 ± 0.4 5.2 ± 0.3
Rubb12-tri 2.3 ± 0.3 5.5 ± 0.7
a Data represent the mean of duplicate experiments ± SE.
b Values determined after 24 h (L3) and 48 h (adult) incubation with compounds.
Fig. 4. Activity of ruthenium complexes against T. muris adult parasites. Survival of
cultured worms in RPMI medium after treatment with Ru complexes (50 μM) for 24 h.
Albendazole was used at 200 μg/ml. Experiments were performed in duplicate and data
represents the average of these two experiments ± SE.
Fig. 5. Action of Rubb12-mono and Rubb12-tri on adult T. muris AChE activity.
Worms were cultured in RPMI for 24 h in the presence of a sub-lethal dose (6.25 μM) of
Rubb12-mono or Rubb12-tri or PBS (three groups of five worms were used for each
treatment). Triton X-100-soluble extracts were made from each group of worms (so, three
extracts per treatment) and 30 μg of each extract was used for enzyme activity assays.
Data is the average of assays run on triplicate extracts and three technical replicates of
each assay± SE. Differences were measured by ANOVA. ****P ≤ 0.0001.
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PAS of AChE located at the rim of the active-centre gorge through a
combination of electrostatic and hydrophobic interactions (Meggers,
2009). The tri- and tetra-nuclear complexes showed greater activity
compared to mononuclear complexes, presumably due to the presence
of the flexibly-linked multiple metal centres which may provide more
interactions (electrostatic and hydrophobic) with the PAS, or each in-
dividual centre may contribute nonspecific additional points of contact.
That the activity of the ruthenium complexes varied between T. muris
and A. caninum extracts is likely due to differences in enzyme ortho-
logues and the existence of multiple isoforms of AChE which are present
in different helminth species (Arnon et al., 1999; Selkirk et al., 2005).
Encouraged by the activity of ruthenium complexes in T. muris adult
parasite extracts, their effect against the L3 and adult stages in vitro
were examined. With minor differences in sensitivity, Rubb12-mono and
Rubb12-tri showed excellent activity against both stages of the parasite
with both complexes exhibiting dose-dependent lethal effects.
However, the results of motility experiments did not correlate with
inhibition of enzyme activity in worm extracts, especially with Rubb12-
mono, which was one of the most effective compounds against both L3
and adult parasites, but not with regards to inhibiting AChE activity in
extracts. This is possibly due to the differential accessibility of inhibitor
to enzyme in an extract preparation compared to a living parasite.
Another explanation is that the mechanism of action of ruthenium
complexes is multi-faceted and not just confined to AChE inhibition.
AChE activity significantly decreased in extracts made from cultured
worms after treatment with sub-lethal concentrations of Rubb12-mono
and Rubb12-tri ruthenium complexes, suggesting that ruthenium com-
plexes are active against T. muris through AChE inhibition, but the
possibility of the compounds exerting their nematocidal activity
through interaction with other targets cannot be discounted given their
documented ability to interact with molecules other than AChE, such as
protein and lipid kinases (Meggers, 2009). There are numerous reports
in the literature documenting the development of drug resistance in
parasites due to mutation of the compound's target molecule (for ex-
ample, benzamidazole resistance in nematodes due to single nucleotide
polymorphisms in β-tubulin (Von Samson-Himmelstjerna et al., 2007)
and mutation of a schistosome sulfotransferase resulting in resistance to
oxamniquine (Valentim et al., 2013), and so the use of a drug that is
directed against multiple molecular targets may decrease the chance of
resistance evolving.
Rubb12-mono was one of the most effective compounds with regards
to in vitro anti-Trichuris activity and was therefore tested for efficacy in
a mouse model of Trichuris infection. Surprisingly, Rubb12-mono was
found to be more toxic by oral administration than what has been re-
ported for simple polypyridylruthenium complexes (eg: [Ru(phen)
3]2+) (Brandt et al., 1954). This is probabably due to a higher rate of
absorption of Rubb12-mono from the intestine into the blood. The
complex showed promising in vivo activity at tolerated doses in mice,
with treatment resulting in reductions in worm (only significant in tria1
1) and egg counts (significant in both trials), compared to controls.
Rubb12-mono-treated mice in trial 2 had a significantly (P = 0.0103)
higher worm load than those in trial 1 and this may explain the reduced
efficacy of Rubb12-mono in the repeat trial. Regardless of the variation
in parasite load, reduction in egg count was not only significant in both
trials but also more pronounced than worm decrease, implying that egg
count reduction was not just concomitant with worm burden reduction
and that Rubb12-mono treatment affected parasite maturation and fe-
cundity. Further, parasites recovered from Rubb12-mono-treated mice
showed significantly decreased AChE activity than those harvested
from control mice (consistent with in vitro results), suggesting that
nematocidal activity was a result of drug-induced inhibition of enzyme
activity. Since reductions in both worm and egg counts are required for
efficacy of anthelmintics, the in vivo results suggest the potential of
Rubb12-mono as a drug lead for the development of novel nematocides
to reduce infection pathology and interrupt disease transmission. Fur-
ther, due to the uniquely shared neurobiology of helminths compared
with higher eukaryotes (Thompson et al., 1996), we believe ruthenium
complexes could exert broad spectrum anthelmintic activity while
being relatively non-toxic and, due to the modular nature of these
compounds, these drugs could be tailored to target specific regions of
molecules, further enhancing their activity and selectivity.
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